share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股SEC公告 ·  09/03 08:06

Moomoo AI 已提取核心訊息

On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.
On September 3, 2024, Recursion Pharmaceuticals, Inc. ("Recursion") announced the top-line results of its SYCAMORE trial, a Phase 2 study for REC-994 in symptomatic cerebral cavernous malformation (CCM) patients. The trial met its primary endpoint of safety and tolerability and showed encouraging trends in MRI-based exploratory efficacy measures at the highest dose. Recursion plans to advance the development of REC-994 for CCM treatment and intends to discuss further clinical studies with the FDA. Additionally, Recursion has entered into a transaction agreement with Exscientia plc ("Exscientia"), which, subject to conditions including stockholder approvals, will result in Recursion acquiring Exscientia. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts anticipated over the next 18 months. The transaction is projected to close by early 2025, with Recursion shareholders owning approximately 74% and Exscientia shareholders owning approximately 26% of the combined entity. The merger aims to leverage technology to discover and develop high-quality medicines efficiently and at scale.
2024年9月3日，Recursion Pharmaceuticals, Inc.（「Recursion」）宣佈其SYMAMORE試驗的最新結果。這是一個用於症狀性腦海綿狀血管瘤（CCM）患者的2期研究REC-994。該試驗在安全性和耐受性方面達到了主要終點，並且在最高劑量下MRI基於的探索性療效評估方面顯示出令人鼓舞的趨勢。Recursion計劃推進REC-994用於CCM治療的開發，並打算與FDA進一步討論臨床研究。此外，Recursion已與Exscientia plc（「Exscientia」）達成交易協議，根據條件包括股東批准，Recursion將收購Exscientia。預計合併後...展開全部
2024年9月3日，Recursion Pharmaceuticals, Inc.（「Recursion」）宣佈其SYMAMORE試驗的最新結果。這是一個用於症狀性腦海綿狀血管瘤（CCM）患者的2期研究REC-994。該試驗在安全性和耐受性方面達到了主要終點，並且在最高劑量下MRI基於的探索性療效評估方面顯示出令人鼓舞的趨勢。Recursion計劃推進REC-994用於CCM治療的開發，並打算與FDA進一步討論臨床研究。此外，Recursion已與Exscientia plc（「Exscientia」）達成交易協議，根據條件包括股東批准，Recursion將收購Exscientia。預計合併後的公司將擁有多樣化的臨床和近臨床項目組合，未來18個月內預計將公佈約10個臨床結果。預計交易將於2025年初完成，Recursion股東將擁有合併實體的約74％的股權，Exscientia股東將擁有約26％的股權。該合併旨在利用科技高效、大規模地發現和開發高質量的藥物。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間